INO stock: buy or sell

INO stock price: $9.01 1.92% At close on Apr 15th, 2021

Updated on:
Apr 16th, 2021


INO stock brief

  • Inovio Pharmaceuticals stock went up 1.92% to close at $9.01 on the stock market today, after 3 consecutive sessions in green.
  • From the chart point view, price is drawing an scaled downtrend since last February with lower tops and lower bottoms. this downtrend marked a -52.58% loss(from its highs at $19.00).

Should I buy Inovio Pharmaceuticals stock?

All successful traders recommend adhering to a trading strategy and not make decisions based on subjective opinions, rumors or feelings. Trading strategies are meant for helping you in the decision process of what stocks to pick and when is the best moment to buy them. At, we like to use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best

Is $INO stock a buy?

In the current situation of Inovio Pharmaceuticals there is not any eligible buy setup. This doesn't mean we expect a selloff for $INO in the next few days, or that it may not rise higher. Simply, it doesn't match our recommended trading systems

Should I sell Inovio Pharmaceuticals stock?

How to know when is it time to sell Inovio Pharmaceuticals stock?. Trading strategies allow us to avoid impetuous decisions based on our feelings or the buzz surrounding the market. Our trading system selects very simple strategies to guide us on when is a good time to sell our shares. Be aware that these strategies should not be used for shorting Inovio Pharmaceuticals stock

A golden rule is that you should not hold a trading operation that yields losses greater than those expected at the time of the buy. The timing to sell your stock always has to be determined by the stop-loss (automatic or manual)

Is it time to sell Inovio Pharmaceuticals stock?

In the current situation of Inovio Pharmaceuticals there is not any eligible sell setup, so Inovio Pharmaceuticals stock holders with operations in profit can keep their positions

Inovio Pharmaceuticals ratings

In the last month, 2 analyst ratings were published for Inovio Pharmaceuticals

Inovio Pharmaceuticals analysts' ratings - Last 30 days
Brokerage firmRating
Mar 23rd, 2021
Bank of America Neutral
Mar 29th, 2021
Bank of America Neutral

Inovio Pharmaceuticals stock analysis

Inovio Pharmaceuticals continues in downtrend since last February, and has droppped a -52.58%. Like in all downtrends, the stock oscillates drawing lower tops and bottoms. In this case, we have seen 2 consecutive lower tops.

SMAs overview

INO stock SMAs chart

Supports and resistances

The current resistances are:

  • R1: $9.11 (1.11% above)
  • R2: $9.20 (2.11% above)
  • R3: $9.30 (3.22% above)
  • The current support levels are:

  • S1: $8.96 (-0.55% below)
  • S2: $8.83 (-2.00% below)
  • S3: $8.80 (-2.33% below)
  • Bollinger bands

    INO stock Bollinger Bands chart

    Relative strength index

    The has been between the the levels of 30 and 70 for many weeks, and therefore, without this indicator really serving to help us make any decisions.

    INO stock RSI chart

    Inovio Pharmaceuticals stock price history

    Inovio Pharmaceuticals IPO was on Dec 8th, 1998 priced at $60.00 per share1. Since then, INO stock declined by -84.98%. An investment of thousand dollars on the IPO would be valued $150.17 today.

    1: Adjusted price after possible price splits or reverse-splits

    INO stock price history chart

    Price target for Inovio Pharmaceuticals stock

    How much a stock will be priced tomorrow or next week is quite unpredictable. However, many stock price predictions are posted every day by banks, financial institutions and independent analysts.

    The following table shows the price forecasts published by analysts in the last 30 days. If you are a small investor you don't have to trade based on these projections.

    There are 2 price forecasts released for Inovio Pharmaceuticals that average $13.00. That is a 44.28% than the current price ($9.01).

    Inovio Pharmaceuticals stock price predictions
    Brokerage firmPrice target
    Mar 23rd, 2021
    Bank of America $13.00
    Mar 29th, 2021
    Bank of America $13.00

    Earnings and financials

    Inovio Pharmaceuticals, Inc. ($INO) reported quarterly earnings of $-0.14 per share in early March, highly enhancing the analysts consensus estimate of $-0.22 per share. This quarterly report represents an earnings surprise of 36.36%. Company's turnover was $5.6 million compared to $1.1 million predicted by market consensus.

    In comparing, the EPS for the same quarter last year was $-0.38, so reported EPS is a improvement of 63.16%. Looking at revenue, figures exploded a 1,896.72% compared to $2.8M same quarter 12 months ago.

    INO ($INO) is hosting the Q1 earnings call mid next May.

    Inovio Pharmaceuticals performance

    INO performance compared
    Inovio Pharmaceuticals ($INO) -11.60% -2.70% -30.20%

    The comments written in this article are personal and not recommendations for you to buy or sell shares. The author of this article does not have an understanding of the individual scenarios of the reader, his or her own finances or what is in his or her best interest at any given time. All users should speak with their financial advisor before buying or selling any securities Viewpoints are posted for informational motives only

    INO summary

    Thursday, April 15th, 2021
    Day range$8.85 - $10.37
    Previous close$8.84
    Session gain1.92%
    Average true range$0.55
    50d mov avg$10.78
    100d mov avg$10.73
    200d mov avg$13.05
    Earnings dateMay 10th, 2021

    Frequently asked questions

    What is Inovio Pharmaceuticals stock symbol?

    Inovio Pharmaceuticals, Inc. is a public company trading in the US stock market with the INO symbol

    Is Inovio Pharmaceuticals stock a buy or sell?

    Inovio Pharmaceuticals received 2 ratings in the last 30 days: 0 bullish, 0 bearish and 2 neutral.

    Will INO go up?

    Inovio Pharmaceuticals had different price predictions posted by analysts in the last month forecasting the target price to $13.00. That is a 44.28% than the last price ($9.01).